Safety of adeno-associated virus gene therapy vectors: a current evaluation.
about
Gene therapy in clinical medicineOverexpression of the astrocyte glutamate transporter GLT1 exacerbates phrenic motor neuron degeneration, diaphragm compromise, and forelimb motor dysfunction following cervical contusion spinal cord injury.Enhanced efficacy of combination therapy with adeno‑associated virus-delivered pigment epithelium-derived factor and cisplatin in a mouse model of Lewis lung carcinoma.Cardiac gene therapyRecombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors.Strategies for manufacturing recombinant adeno-associated virus vectors for gene therapy applications exploiting baculovirus technology.Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakageNovel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.Cardiac gene therapy with SERCA2a: from bench to bedsideDevelopment of Novel Recombinant AAV Vectors and Strategies for the Potential Gene Therapy of Hemophilia.Drug delivery systems for the treatment of ischemic stroke.Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease.Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown.Stable antibody expression at therapeutic levels using the 2A peptide.Butyrylcholinesterase gene transfer in obese mice prevents postdieting body weight rebound by suppressing ghrelin signaling.The transduction of rat submandibular glands by an adenoviral vector carrying the human growth hormone gene is associated with limited and reversible changes at the infusion site.Targeted delivery of siRNA.Long-Term Correction of Diabetes in Mice by In Vivo Reprogramming of Pancreatic Ducts.Gene therapy for Parkinson's disease
P2860
Q24680275-9CBBFD8B-0E0B-44BF-8816-A2F2D1C5F0E8Q33671711-FF5D427F-2AA5-4CE0-B69F-94D1BFB5F052Q33747690-2E85D1E9-5E5D-4E85-B62A-5A934BE494DAQ34409721-5D38D766-C0F7-4136-9488-705415C8540BQ36144935-A52189E1-5C8B-45AB-A671-47B277999535Q36150495-C0E0E99C-1C04-4019-A2DB-FB64F095B979Q36925619-697D46BB-7040-44DF-9FCE-C26597AB577FQ37267083-3BAF4A0A-728A-4E72-8613-A4E9D914C52BQ37743813-14590BD5-1F9E-4831-A8A1-C0BCB4E73692Q37811189-82371C8E-0E96-41E7-9290-4FF012296C4DQ38069585-68DF821F-43D2-4819-8DE1-FFC8589F20A2Q38073181-714A57CB-563F-4866-9C8F-07A5857DC455Q38112216-2A7F4900-C500-4B13-A331-66EAF90645B1Q39715457-0DB4E541-92CC-469C-9C9C-5CEFBB3BB52BQ40434248-72E87932-8237-4789-9939-649C8BA715FBQ41925326-A4B62570-1C8B-4D18-A1BC-18DE43DB33F9Q41944937-3B5E15B7-3D9F-46B3-865E-4BB3AFC68EBEQ42577519-BBCBFB4A-BF51-4C3A-8938-B70C3A894681Q52650846-60DA7EB0-1892-495D-905E-ADC4FFEC5849Q58913419-1BE625BD-0992-4C87-94A9-5F360F194122
P2860
Safety of adeno-associated virus gene therapy vectors: a current evaluation.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Safety of adeno-associated virus gene therapy vectors: a current evaluation.
@ast
Safety of adeno-associated virus gene therapy vectors: a current evaluation.
@en
type
label
Safety of adeno-associated virus gene therapy vectors: a current evaluation.
@ast
Safety of adeno-associated virus gene therapy vectors: a current evaluation.
@en
prefLabel
Safety of adeno-associated virus gene therapy vectors: a current evaluation.
@ast
Safety of adeno-associated virus gene therapy vectors: a current evaluation.
@en
P2093
P2860
P356
P1476
Safety of adeno-associated virus gene therapy vectors: a current evaluation.
@en
P2093
Karin Jooss
Mark S Sands
Paul E Monahan
P2860
P356
10.1517/14740338.1.1.79
P407
P577
2002-05-01T00:00:00Z